Why Hims & Hers Health Is the Ultimate $20 Stock to Buy for Long-Term Growth

Hims & Hers Health: The Ultimate Growth Stock

I challenge you to name another $20 stock with more long-term potential. Raging hot inflation has made it harder to find value in anything these days. A $20 bill doesn't go as far as it once did. But don't get discouraged; that money can go a long way if you know where to put it. Yes, even in the stock market, you can still get a lot for $20.

The Power of GLP-1 Agonists

GLP-1 agonists like Ozempic have taken the healthcare world by storm. These products mimic a hormone that helps suppress appetite and regulate blood sugar, two fundamental aspects of weight loss.

• Hims & Hers Health recently announced it would start carrying name-brand GLP-1 agonists and offering customized compounds containing active ingredients.
• The compounds are a big deal because they're significantly cheaper than the name-brand drugs, as much as 85% less.

Expanding Opportunities in Healthcare

Strip away the weight-loss category, and you still have a rapidly growing business thriving in multiple ways today. The company built its 1.7 million customer base on other healthcare categories, such as sexual health, dermatology, mental health, and hair loss.

1. Hims & Hers is on track to eclipse $100 million in revenue by the end of next year, with a significant upside in that number due to the launch of GLP-1 products.
2. The company's revenue growth continues to impress, showing 46% year-over-year growth as it approaches a billion dollars in annual revenue.

Investing in Future Growth

Shares of Hims & Hers have seen a 50% increase over the past month, indicating potential growth opportunities. With the company turning its first profit and analysts raising earnings-per-share estimates, Hims & Hers Health is poised for strong future performance.